Filing Details
- Accession Number:
- 0000921895-18-001867
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-06-01 17:13:25
- Reporting Period:
- 2018-05-30
- Accepted Time:
- 2018-06-01 17:13:25
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1019695 | Arqule Inc | ARQL | Investment Advice (6282) | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 918923 | P L Fund Value Biotechnology | 1 Sansome St 30Th Fl San Francisco CA 94104 | No | No | No | Yes | |
| 1055947 | P/Il L Partners Bvf | 1 Sansome St 30Th Fl San Francisco CA 94104 | No | No | Yes | No | |
| 1056807 | Bvf Inc/Il | 1 Sansome St 30Th Fl San Francisco CA 94104 | No | No | Yes | No | |
| 1102444 | Biotechnology Value Fund Ii Lp | 1 Sansome St 30Th Fl San Francisco CA 94104 | No | No | No | Yes | |
| 1233840 | N Mark Lampert | 1 Sansome St 30Th Fl San Francisco CA 94104 | No | No | Yes | No | |
| 1660683 | Biotechnology Value Trading Fund Os Lp | P.o. Box 309 Ugland House Grand Cayman E9 KY1-1104 | No | No | No | Yes | |
| 1660684 | Ltd. Os Partners Bvf | P.o. Box 309 Ugland House Grand Cayman E9 KY1-1104 | No | No | No | Yes |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.01 Par Value Per Share | Disposition | 2018-05-30 | 547,860 | $5.00 | 4,682,669 | No | 4 | S | Direct | |
| Common Stock, $0.01 Par Value Per Share | Disposition | 2018-05-30 | 312,266 | $5.00 | 3,186,044 | No | 4 | S | Direct | |
| Common Stock, $0.01 Par Value Per Share | Disposition | 2018-05-30 | 175,813 | $5.00 | 771,305 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock, $0.01 Par Value Per Share | Warrants | $1.75 | 2021-10-11 | 1,201,053 | 1,201,053 | Direct | |
| Common Stock, $0.01 Par Value Per Share | Warrants | $1.75 | 2021-10-11 | 823,231 | 823,231 | Direct | |
| Common Stock, $0.01 Par Value Per Share | Warrants | $1.75 | 2021-10-11 | 199,687 | 199,687 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2021-10-11 | 1,201,053 | 1,201,053 | Direct |
| 2021-10-11 | 823,231 | 823,231 | Direct |
| 2021-10-11 | 199,687 | 199,687 | Direct |
Footnotes
- This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- Securities owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- Securities owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
- The Warrants are currently exercisable, for $1.75 per share, subject to adjustment pursuant to the terms of the Warrants and expire on October 11, 2021. The Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.9% of the shares of Common Stock outstanding immediately after giving effect to such exercise.
Billionaire Hedge Funds
